181 related articles for article (PubMed ID: 20846109)
1. Transport of therapeutic vanadium and ruthenium complexes by blood plasma components.
Pessoa JC; Tomaz I
Curr Med Chem; 2010; 17(31):3701-38. PubMed ID: 20846109
[TBL] [Abstract][Full Text] [Related]
2. Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 2. Characterization of sulfonate derivatives of quercetin and morin, interaction with the bioligands of the plasma and preliminary biotransformation studies.
Sanna D; Ugone V; Pisano L; Serra M; Micera G; Garribba E
J Inorg Biochem; 2015 Dec; 153():167-177. PubMed ID: 26281973
[TBL] [Abstract][Full Text] [Related]
3. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
4. V
Sanna D; Ugone V; Sciortino G; Buglyó P; Bihari Z; Parajdi-Losonczi PL; Garribba E
Dalton Trans; 2018 Feb; 47(7):2164-2182. PubMed ID: 29327005
[TBL] [Abstract][Full Text] [Related]
5. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
[TBL] [Abstract][Full Text] [Related]
6. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
7. On the transport of vanadium in blood serum.
Sanna D; Micera G; Garribba E
Inorg Chem; 2009 Jul; 48(13):5747-57. PubMed ID: 19514735
[TBL] [Abstract][Full Text] [Related]
8. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
[TBL] [Abstract][Full Text] [Related]
9. New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.
Sanna D; Micera G; Garribba E
Inorg Chem; 2010 Jan; 49(1):174-87. PubMed ID: 19947643
[TBL] [Abstract][Full Text] [Related]
10. Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity.
Demoro B; Bento-Oliveira A; Marques F; Costa Pessoa J; Otero L; Gambino D; F M de Almeida R; Tomaz AI
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394747
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in ruthenium anticancer drugs.
Levina A; Mitra A; Lay PA
Metallomics; 2009 Nov; 1(6):458-70. PubMed ID: 21305154
[TBL] [Abstract][Full Text] [Related]
12. Interaction of VO2+ ion with human serum transferrin and albumin.
Sanna D; Garribba E; Micera G
J Inorg Biochem; 2009 Apr; 103(4):648-55. PubMed ID: 19201482
[TBL] [Abstract][Full Text] [Related]
13. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
Groessl M; Hartinger CG; Polec-Pawlak K; Jarosz M; Keppler BK
Electrophoresis; 2008 May; 29(10):2224-32. PubMed ID: 18512673
[TBL] [Abstract][Full Text] [Related]
14. Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs.
Levina A; Chetcuti ARM; Lay PA
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139158
[TBL] [Abstract][Full Text] [Related]
15. Protein binding by dinuclear polypyridyl ruthenium(II) complexes and the effect of cucurbit[10]uril encapsulation.
Li F; Feterl M; Warner JM; Day AI; Keene FR; Collins JG
Dalton Trans; 2013 Jun; 42(24):8868-77. PubMed ID: 23657293
[TBL] [Abstract][Full Text] [Related]
16. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
[TBL] [Abstract][Full Text] [Related]
17. Complexes of gastrin with In
Laval M; Marshall KM; Sachinidis J; Scott A; Eutick M; Baldwin GS
J Biol Inorg Chem; 2017 Oct; 22(7):999-1006. PubMed ID: 28702751
[TBL] [Abstract][Full Text] [Related]
18. Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS.
Marković K; Milačič R; Marković S; Kladnik J; Turel I; Ščančar J
Molecules; 2020 Mar; 25(7):. PubMed ID: 32225069
[TBL] [Abstract][Full Text] [Related]
19. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
20. Interaction of insulin-enhancing vanadium compounds with human serum holo-transferrin.
Sanna D; Micera G; Garribba E
Inorg Chem; 2013 Oct; 52(20):11975-85. PubMed ID: 24090437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
